Sartor R B
University of North Carolina at Chapel Hill, USA.
Gastroenterol Clin North Am. 1995 Sep;24(3):475-507.
Although the causes, events initiating and triggering inflammation, and the precise immunoregulatory defects of IBD are still not known, investigations have provided a better understanding of the mechanisms of perpetuation of inflammation, genetic susceptibility, tissue injury, and symptoms. Ulcerative colitis and Crohn's disease are related disorders that probably share susceptibility genes and have similar nonspecific inflammatory mediator profiles. These diseases, however, almost certainly have different causes and respond to different antigenic stimuli. It is probable that both ulcerative colitis and Crohn's disease represent heterogenic groups of diseases that share similar mechanisms of tissue damage but have different initiating events and immunoregulatory abnormalities. Rodent models demonstrate that a wide variety of initial injuries or perturbations of immunoregulatory pathways can lead to similar phenotypes of intestinal injury, and human studies show evidence of genetic heterogeneity. It is equally apparent from these models that initiating and perpetuating mechanisms are entirely distinct and that the intestine has a remarkable ability to heal. Chronicity of disease depends on continued exposure to toxic luminal components, most commonly of bacterial origin, and genetically determined host susceptibility. Precise mechanisms of differential genetic susceptibility remain unclear, but defective down-regulation of inflammation is consistent with clinical and experimental observations. The author proposes the following sequence of events (Fig. 9). Nonspecific intestinal inflammation can be induced by a wide variety of enteric infections or ingested toxins. Resultant increased mucosal permeability leads to enhanced uptake of toxic luminal bacterial products, which potentiate local injury. The vast majority of hosts respond to these injurious events by promptly down-regulating the inflammatory response and rapidly healing the mucosal damage without residual scarring. The genetically susceptible host, however, who lacks the ability to suppress the inflammatory response efficiently, has inappropriate amplification of the immune cascade. In response to constant exposure to phlogistic luminal constituents, these patients develop an unrestrained inflammatory response, leading to tissue destruction, chronic inflammation, and fibrosis. Thus, IBD is caused by a genetically determined defective down-regulation of inflammation driven by ubiquitous antigens. Luminal anaerobic bacterial antigens are the stimuli in Crohn's disease, but ulcerative colitis may be caused by functionally abnormal aerobic bacteria or primary defects in epithelial cell physiology. Spontaneous or therapy-induced remissions can be achieved, but the risk of reactivation of inflammation is high because of the frequent exposure to triggering episodes that can reignite the inflammatory cascade. [formula: see text] This theory suggests that the intestine is in a constant state of controlled inflammation, mediated by a balance between aggressive luminal forces and host protective mechanisms (Fig. 10). This delicate balance can be deranged by any number of environmental triggering events and is in dysequilibrium in IBD. Amplification of the inflammatory response activates effector cells and cascades of soluble inflammatory molecules, which mediate tissue injury and physiologic responses leading to symptoms of IBD. These relatively nonspecific events are the target of most current therapeutic agents, which can inhibit but not completely block intestinal inflammation because of the overwhelming number of parallel pathways involved. Specific inhibition of selected effector molecules is intellectually intriguing but is less likely to paralyze the inflammatory response during clinically apparent inflammation than is blockade of key immunoregulatory cells and molecules. Better understanding of initiating, perpetuating, and immunoregulatory mechanisms should provide more
尽管炎症性肠病(IBD)的病因、引发和触发炎症的事件以及确切的免疫调节缺陷仍不明确,但研究已使我们对炎症持续存在、遗传易感性、组织损伤和症状的机制有了更好的理解。溃疡性结肠炎和克罗恩病是相关疾病,可能共享易感基因且具有相似的非特异性炎症介质谱。然而,这些疾病几乎肯定有不同的病因,并对不同的抗原刺激产生反应。溃疡性结肠炎和克罗恩病很可能都代表异质性疾病组,它们具有相似的组织损伤机制,但起始事件和免疫调节异常不同。啮齿动物模型表明,多种初始损伤或免疫调节途径的扰动可导致相似的肠道损伤表型,而人体研究也显示出遗传异质性的证据。从这些模型中同样明显的是,起始机制和持续机制完全不同,而且肠道具有显著的愈合能力。疾病的慢性化取决于持续接触有毒的肠腔成分,最常见的是细菌来源的成分,以及遗传决定的宿主易感性。不同遗传易感性的确切机制仍不清楚,但炎症下调缺陷与临床和实验观察结果一致。作者提出了以下事件序列(图9)。多种肠道感染或摄入的毒素可诱发非特异性肠道炎症。由此导致的黏膜通透性增加会增强对有毒肠腔细菌产物的摄取,从而加剧局部损伤。绝大多数宿主通过迅速下调炎症反应并快速愈合黏膜损伤且不留残余瘢痕来应对这些损伤事件。然而,缺乏有效抑制炎症反应能力的遗传易感宿主会出现免疫级联反应的不适当放大。由于持续接触炎性肠腔成分,这些患者会产生不受控制的炎症反应,导致组织破坏、慢性炎症和纤维化。因此,IBD是由普遍存在的抗原驱动的、遗传决定的炎症下调缺陷所致。肠腔厌氧细菌抗原是克罗恩病的刺激因素,但溃疡性结肠炎可能由功能异常的需氧菌或上皮细胞生理学的原发性缺陷引起。可以实现自发缓解或治疗诱导的缓解,但由于频繁接触可重新引发炎症级联反应的触发事件,炎症复发的风险很高。[公式:见正文] 该理论表明,肠道处于由侵袭性肠腔力量与宿主保护机制之间的平衡介导的持续受控炎症状态(图10)。这种微妙的平衡可能因任何数量的环境触发事件而失调,在IBD中处于失衡状态。炎症反应的放大激活效应细胞和可溶性炎症分子级联反应,介导组织损伤和导致IBD症状的生理反应。这些相对非特异性的事件是大多数当前治疗药物的靶点,由于涉及大量平行途径,这些药物可以抑制但不能完全阻断肠道炎症。对选定效应分子的特异性抑制在理论上很有吸引力,但在临床明显炎症期间,与阻断关键免疫调节细胞和分子相比,不太可能使炎症反应瘫痪。对起始、持续和免疫调节机制的更好理解应能提供更多……